Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial

izokibep (ABY-035) - Affibody, ACELYRIN

https://www.eventscribe.net/2022/ACRConvergence/fsPopup.asp?Mode=presInfo&PresentationID=1131112

Frank Behrens1; Peter Taylor2; Philip J Mease3; Paul Peloso4; Dieter Wetzel5; Nicolai Brun5; Brian Wiens6; Jan Brandt-Juergens7; Edit Drescher8; Eva Dokoupilova9; Anna Rowińska-Osuch10; Nadia Abdel- Kader Martin11; Kurt de Vlam12

Sep 17, 2022